Novartis’ $12bn Avidity bet falters on late-stage del-desiran flop

Analysts previously noted that del-desiran's success in HARBOR would be a key justifier for the price tag of Novartis' Avidity acquisition. Analysts previously noted that the HARBOR study’s success would be a key justifier of the Avidity acquisition’s price tag. Novartis will now assess the next steps for del-desiran’s development programme. Credit: 24K-Production / Shutterstock.com. Novartis’ Avidity Biosciences-acquired therapy, delpacibart etedesiran (del-desiran), has stumbled in a Phase III muscle wasting disorder study, dealing another blow to the company’s pipeline as it faces key patent expiries within its portfolio. This late-stage miss stems from the HARBOR study (NCT06411288), in which Novartis…

Source: Clinical Trials Arena